Dr. Sang Won Lee, MD

Dr. Lee practices at Keck Medicine of USC - USC Roski Eye Institute - Ophthalmology - HOPD in Los Angeles, California.

Dr. Lee's NPI, 1386651867, was assigned on August 1, 2006. Dr. Lee graduated from New York University School of Medicine in 1993. Dr. Lee holds California license G137773.

Dr. Lee's primary practice is Keck Medicine of USC - USC Roski Eye Institute - Ophthalmology - HOPD, at 1450 San Pablo St, Los Angeles, CA 90033.

Dr. Lee's primary practice is Keck Medicine of USC - USC Roski Eye Institute - Ophthalmology - HOPD in Los Angeles, California. Dr. Lee is also affiliated with Keck Hospital of USC. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Lee to 1 more group practice or clinic and 1 other site, each named with a free account. Dr. Lee's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lee practices, 4 sites in all. Vendor and product names are available with a free account.

Colon and rectal surgery is Dr. Lee's primary specialty in the NPI Registry, under taxonomy code 208C00000X. Dr. Lee is board certified in colon & rectal surgery by the American Board of Colon and Rectal Surgery. Dmand AI has Dr. Lee's licenses on file in 3 states: California, Florida and New York.

Dmand AI lists colonoscopy, colon removal, gastrointestinal obstruction and hemorrhoids among the conditions Dr. Lee treats.

CMS data shows 328 Medicare services from Dr. Lee across 11 procedure codes in 2024, for 188 Medicare patients. Medicare paid $37,281 for them.

CMS counts 188 Medicare patients who saw Dr. Lee in 2024. The largest group is 65 to 74, with 103 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 49% are also on Medicaid. Their average risk score is 3.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lee's median patient age at 62, with 40% women.

In 2024, Dr. Lee wrote 46 Medicare Part D claims for 29 patients. 85% of them were for generic drugs. CMS names the drug for 33 of them, across 2 drugs with 11 or more claims each, at $88 in total drug cost. In 2023, CMS named 63 claims across 3 drugs.

Dr. Lee accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lee as offering telehealth. CMS counts 71 procedures of colonoscopy by Dr. Lee, more than 71% of the clinicians it reports for that procedure.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 52 papers to Dr. Lee, published from 2005 to 2025. 2024 was the busiest year, with 9. The most frequent topics are Biofilms, Anti-Bacterial Agents and Biocompatible Materials. Dr. Lee has published most often in J Pediatr Soc North Am. Dr. Lee's most frequent co-authors are Bernard Nii Yeboah Burgesson, MD, Namrata S. Chandhok, MD and Antonia F. Chen, MD.

Dmand AI links Dr. Lee to 2 clinical trials. Conditions studied include Crohn Disease, Rectal Neoplasms and Inflammatory Bowel Diseases.

CMS Open Payments shows 367 general payments to Dr. Lee from 35 drug and device companies from 2016 to 2025. Acquisitions make up the largest share, 90% of the total. Stryker Corporation paid the most, $2,274,946. It also lists 1 research payment totaling $12,647 in 2020.

Dmand AI lists 28 awards for Dr. Lee, most recently Best Doctors in New York list in 2014.

Dr. Lee graduated from New York University School of Medicine in 1993. Dr. Lee is a member of ACS, ASCRS, AAS, SSAT and SAGES.

Dr. Lee is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.